Franchise killer: Are Regeneron and Sanofi about to get handed their walking papers on PCSK9?
One top analyst believes that the Medicines Company may soon be in a position to do what years of payer resistance to Regeneron and Sanofi’s would-be PCSK9 blockbuster Praluent has so far failed to do:
So here’s the reasoning, and it’s compelling.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.